What links a champion woman runner, a premier-league soccer team, and a 53 year old male biochemist? Citizens of Dundee, Scotland's fourth largest city, will know the answer: all three are local heroes.
And no wonder biochemist Philip Cohen is a local hero. Over the past nearly 30 years, he has played midwife to the birth of a scientific megapolis on the banks of the River Tay. Today, redundant shipyards and jute factories have given way to research laboratories and technology parks. Biomedical research is now the city's third largest industry, and growing. Already, it rivals Oxford and Cambridge as a centre of bioscientific excellence.
Explanations of the 'Dundee phenomenon' vary, but generally begin or end with Philip Cohen. "He has turned a sleepy provincial university into one of the best biochemistry departments in the country," says one fellow biochemist. "Most people start by thinking Dundee is the last place they'd want to work," comments a university colleague. "Then Philip persuades them to come."
His scientific reputation is part of the lure. A pioneer in the study of protein phosphorylation, he is now "one of the top three people in the world in the field of signal transduction," says one US-based ex-student. Cohen arrived in Dundee in 1971, bearing a first-class degree and a PhD from University College London and fresh from a two-year stint in Seattle with Edmond Fischer, who later shared a Nobel Prize for his discovery of the first protein kinase. "People told me Dundee was in the middle of nowhere, but after my stint in the States, distances didn't bother me," Cohen says. After all, Seattle was several hours from the nearest research centre in San Francisco. "All the same, I was naive. It never occurred to me that Dundee hadn't the money to buy the equipment I wanted." But after a few lean years, Cohen perfected the art of getting grants, and is proud that he's spent only four years on the university payroll.
Some fellow researchers find him "impossibly arrogant on a personal level -he always has to have the last word on everything." Certainly if Cohen harbours selfdoubt, he has buried the tell-tale signs more successfully than most. But one former student predicted that I would find him charming, and so I did.
Yet former students say he is demanding and prone to tantrums. He is infamous for his 'lab rules', which stipulate the hours a student must work and forbid the reading of newspapers on the premises. Absences of more than 20 minutes must be accounted for. Students fresh from undergraduate freedoms may bridle at such restrictions, but one ex-student wryly comments that although he thought the rules "ridiculous when I started, now that I'm starting my own lab they actually seem quite reasonable." Cohen remains unrepentant. "Research is a vocation; if they don't want to do it, they shouldn't be here," he says. "I have a responsibility to tell students what they need to do to be successful." And everyone agrees that a lot of very successful people have come out of his laboratory over the past couple of decades.
He certainly likes to win. "If I do anything, I like to do it competitively -otherwise it's just messing around." A keen golfer with a handicap of 13, he also plays bridge and chess to a high standard. His daughter, following her parents into biomedical research as a graduate student in immunology at Oxford, is also Britain's top young bridge player on the international circuit.
Yet the uncompetitive world of natural history also intrigues Cohen, R270 Current Biology, Vol 9 No 8 Philip Cohen, ahead of the game who likes to watch the birds and seals on the estuary, or collect wild mushrooms from the unspoilt countryside near Dundee. The son of a chemist who perfected the printing ink technology for the Sunday Times' first colour magazine, the young Cohen excelled in school science but also spent long hours bird-watching and pond dipping around his home on the outskirts of London. "Naively, I imagined that biochemistry would be somewhere in between." Today, he is an energetic, tireless and very persuasive campaigner for British biochemistry, colleagues say, even encouraging students to publish in British or European journals rather than American ones. "Many of my most cited papers have been published in Current Biology, the European Journal of Biochemistry and FEBS Letters," he notes. "Americans are always looking for an excuse not to read European journals. We are cutting our own throats if we don't publish in them."
Success has come through "hard work, good luck and some intuition," Cohen says. These days, he reckons his instant recall may be less sharp than it was but his intuition is getting better. He began to study protein phosphorylation when it appeared to be a mechanism linked only to glycogen metabolism. "Now it seems that protein phosphorylation regulates everything."
Cohen may have been lucky in his early research directions but he says he has also developed a gift for spotting the unexpected. Five years ago, "I had never done anything with a pharmaceutical company," Cohen says. Now, long-term industrial collaborations to generate "huge batteries of specific kinase and phosphatase inhibitors" are a major goal, Cohen reckons. "This is the way to solve cell signalling," his intuiton tells him, and some of the pharmaceuticals giants are listening.
Gail Vines is a freelance science writer based in Cambridge, UK.
Gazetteer Zeneca
What is it famous for? At the moment, for merging successfully with Swedish drug makers Astra. By joining forces with another mid-sized pharmaceutical company, UK-based Zeneca has leapfrogged to the number one position in the league table of pharmaceutical giants. The combined company, called AstraZeneca, has a 4.3% share of the world's US$251 billion prescription drug market. The closest rivals Merck, Glaxo Wellcome and Novartis are all tied in second place, according to 1998 sales figures.
How did Zeneca begin? Six years ago, Zeneca was spun off from the drug and agrochemical interests of the old Imperial Chemical Industries (ICI).
Where is the new company based?
The corporate headquarters is in London but research will be directed from Sweden. Some 6,000 jobs are expected to be lost over the next three years, mainly in administration.
Why merge? Sir Richard Sykes, Glaxo Wellcome's chairman, summed it up when he said that drug companies come together "not to protect future earnings growth but to increase critical mass to outperform the industry … the more money you can put into research, the stronger the company's going to be." AstraZeneca has the second largest Research & Development budget among the drug companies, at US$1.9 billion, behind both Glaxo Wellcome and Merck, who are tied in first place.
What has Zeneca brought to the partnership? A portfolio of cancer drugs rivalled only by that of Bristol Myers Squibb. Zeneca's leading oncology product, tamoxifen, is the world's most widely prescribed breast cancer medication. Tamoxifen made international headlines last year when the US National Cancer Institute announced -some said prematurely (see Curr Biol 1998, 8 8: :R328) -that the drug can halve the risk of breast cancer in women genetically predisposed to the disease. But Zeneca isn't just a one-drug wonder. Each of the following Zeneca products is the world's top seller in its category: Diprivan, a general anesthetic; Inderal, a β-blocker; and Zestril, used to treat high blood pressure and heart failure. Zeneca is also a top producer of agrochemicals, a business it is keeping in the merged company.
What about Astra's medicine chest? Its ulcer remedy, Losec, is the best-selling prescription drug in the world. Astra is also responsible for Xylocaine, the most widely used local anesthetic in the world.
Is this an equal partnership? Although billed as a "merger of equals", Zeneca's share price was stronger than Astra's at the time of the merger. So Zeneca ends up as the larger partner despite Astra's drugs business being of a similar size.
Who stands to gain? Merck. As part of a divorce settlement that will end a 1982 joint venture between Astra and Merck, AstraZeneca will pay Merck US$1.7 billion up front, and a minimum of US$4.7 billion in 2008. Chiroscience (based in Cambridge, UK) is also smiling. Zeneca has been forced to give up rights to Chirocaine, an anesthetic developed by Chiroscience and under worldwide licence to Zeneca, as its only direct competition would be one developed by Astra. AstraZeneca will have to pay US$16 million to Chiroscience in compensation, and still continue to develop Chirocaine for commercial launch this year.
Isn't everybody doing it? As the names of the major players reveal, the pharmaceutical industry has a strong tradition of mergers -now, even
